32 related articles for article (PubMed ID: 19520186)
1. PPARγ in Atherosclerotic Endothelial Dysfunction: Regulatory Compounds and PTMs.
Luan J; Ji X; Liu L
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833942
[TBL] [Abstract][Full Text] [Related]
2. PPAR Gamma and Angiogenesis: Endothelial Cells Perspective.
Kotlinowski J; Jozkowicz A
J Diabetes Res; 2016; 2016():8492353. PubMed ID: 28053991
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone improves potassium channel remodeling induced by angiotensin II in atrial myocytes.
Gu J; Hu W; Liu X
Med Sci Monit Basic Res; 2014 Oct; 20():153-60. PubMed ID: 25296378
[TBL] [Abstract][Full Text] [Related]
4. Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension.
Chan SL; Sweet JG; Cipolla MJ
FASEB J; 2013 Oct; 27(10):3917-27. PubMed ID: 23783073
[TBL] [Abstract][Full Text] [Related]
5. Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets.
Rohatgi N; Aly H; Marshall CA; McDonald WG; Kletzien RF; Colca JR; McDaniel ML
PLoS One; 2013; 8(5):e62012. PubMed ID: 23650507
[TBL] [Abstract][Full Text] [Related]
6. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kurahashi H; Morita M; Kugita M; Hiki Y; Aukema HM; Yamaguchi T; Calvet JP; Wallace DP; Nagao S
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
[TBL] [Abstract][Full Text] [Related]
7. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.
Sarafidis PA; Lasaridis AN
Am J Hypertens; 2006 Jun; 19(6):646-53. PubMed ID: 16733240
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats.
Desouza CV; Gerety M; Hamel FG
Vascul Pharmacol; 2007 Mar; 46(3):188-94. PubMed ID: 17141574
[TBL] [Abstract][Full Text] [Related]
9. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
10. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.
Aljada A; O'Connor L; Fu YY; Mousa SA
Angiogenesis; 2008; 11(4):361-7. PubMed ID: 18810647
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
13. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.
Desouza CV; Gerety M; Hamel FG
Vascul Pharmacol; 2009; 51(2-3):162-8. PubMed ID: 19520186
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
